$IBRX news
The latest IBRX stock news: headlines, filings, AI summaries and sentiment for $IBRX, updated around the clock.
- ImmunityBio Shares Fall 15% Following Third Quarter Earnings Miss
- ImmunityBio, Inc. - 10-Q Filing
- ImmunityBio Reports Third Quarter Revenue and EPS Misses
- ImmunityBio, Inc. - 8-K Filing
- ImmunityBio, Inc. - 8-K Filing
- ImmunityBio, Inc. - 8-K Filing
- FDA Expands Approval of ImmunityBio's Anktiva to Include Early-Stage Bladder Cancer
- ImmunityBio Shares Rise After Meeting With Turkish President
- Rosen Law Firm Appointed as Lead Counsel in ImmunityBio Securities Class Action
- ImmunityBio, Inc. - 8-K Filing
- Investor Deadline for ImmunityBio Class Action Lawsuit on May 26
- Class Action Lawsuit Filed Against ImmunityBio Following FDA Warning and Stock Drop
- ImmunityBio Secures Exclusive U.S. Rights to Tokyo-Strain BCG for Bladder Cancer Treatment
- ImmunityBio Near Regulatory Approval for Bladder Cancer Immunotherapy
- ImmunityBio Stock Rises on FDA Acceptance of Supplemental BLA for Anktiva
- ImmunityBio Stock Rises on FDA Acceptance for Anktiva Label Expansion
- ImmunityBio Receives FDA Review for Anktiva Label Expansion
- ImmunityBio, Inc. - 8-K Filing
- ImmunityBio Acquires U.S. Rights to BCG Therapy from Japan BCG Laboratory
- Class Action Lawsuit Filed Against ImmunityBio Following FDA Warning and Stock Drop
- Class Action Lawsuit Filed Against ImmunityBio, Inc. Over Alleged Securities Fraud
- Class Action Lawsuit Filed Against ImmunityBio, Inc. (NASDAQ: IBRX) by Berger Montague
- ImmunityBio Expands ANKTIVA Access to Saudi Arabia
- ImmunityBio Faces Securities Law Lawsuit Over Misleading Statements About Anktiva
- ImmunityBio Expands Globally, Driving 266% Share Price Increase in 2026
- ImmunityBio Faces Class Action Lawsuit Over Alleged Misstatements About Anktiva
- Class Action Lawsuit Filed Against ImmunityBio, Inc. (NASDAQ: IBRX) Over Alleged Securities Fraud